ClinicaliQ Trial Snapshot
- Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP — Active Not Recruiting • Phase III • NCT06079359.
- A new drug (ALXN1850) was tested against placebo in children with bone disease to see if it improves bone health.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary purpose of this study is to evaluate the efficacy of ALXN1850 versus placebo on radiographic outcomes in pediatric participants with HPP who have not previously been treated with asfotase alfa. Conditions: Hypophosphatasia Interventions: ALXN1850, Placebo Lead Sponsor: Alexion Pharmaceuticals, Inc. Planned Enrollment: 30 participants